Immunohistochemical surrogate markers of breast cancer molecular classes predicts response to neoadjuvant chemotherapy

Abstract

We confirm the recently defined "triple negative paradox," or rather "hormone receptor negative paradox," that despite the best response to NACT, ERBB2 and triple negative tumors show the worst overall survival because of higher relapse among those with residual disease.